This is a non-core endpoint: only basic statistics are computed.
Carcinoma in situ of skin of upper limb, including shoulder (controls excluding all cancers)
CD2_INSITU_SKIN_UPPERLIMB_EXALLC
No definition available.
Endpoint definition
↥
FinnGen phenotype data
individuals
Apply sex-specific rule None
Check conditions None
Check pre-conditions, main-only, mode, registry filters
Hospital Discharge: ICD-10
D04.6&
Hospital discharge: ICD-9
2326
Cause of death: ICD-10
D04.6&
Cause of death: ICD-9
2326
2 out of 7 registries used, show all original rules.
-
Check minimum number of events None
-
Include endpoints None
-
Remove individuals based on genotype QC
446
CD2_INSITU_SKIN_UPPERLIMB_EXALLC
Control definitions
Control exclude
C3_CANCER, C3_CANCER_WIDE
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D04
Name in latin
Carcinoma in situ cutis regionis deltoideae
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Carcinoma in situ of skin of upper limb, including shoulder (controls excluding all cancers)
based on the number of shared cases.
Broader endpoints:
- Carcinoma in situ of skin of upper limb, including shoulder
- Neoplasms
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
- Any ICDMAIN event in hilmo or causes of death
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 446 | 209 | 237 |
| Unadjusted prevalence (%) | 0.12 | 0.10 | 0.14 |
| Mean age at first event (years) | 74.06 | 74.40 | 73.76 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: CD2_INSITU_SKIN_UPPERLIMB_EXALLC – Carcinoma in situ of skin of upper limb, including shoulder (controls excluding all cancers)
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Carcinoma in situ of skin of upper limb, including shoulder (controls excluding all cancers)
↥Endpoint not on priority list, no data to show.